{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-022823","form_type":"8-K","ticker":"INBS","cik":"0001725430","company_name":"INTELLIGENT BIO SOLUTIONS INC.","filed_at":"2026-05-14T01:08:16+00:00","discovered_at":"2026-05-14T10:10:00.383838+00:00","generated_at":"2026-05-14T10:14:29.423393+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Intelligent Bio Q3 revenue $1.06M (+46% YoY); cartridge sales up 59%","bullets":["Q3 cartridge revenue $703,538, up 59% YoY, representing 66% of total sales.","Gross profit margin expanded to 50.5% in Q3 (vs 46.8% prior year); nine-month margin 49.3%.","Nine-month revenue reached $3.07M, up 39% YoY; cash balance $6.86M at March 31, 2026.","Marketing spend in Q3 down 42% YoY while commercial momentum accelerated.","FDA 510(k) program advancing; new manufacturing partnership and Bouygues UK customer added."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022823","json":"https://secwatch.observer/filing/0001493152-26-022823.json","markdown":"https://secwatch.observer/filing/0001493152-26-022823.md","text":"https://secwatch.observer/filing/0001493152-26-022823.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725430/000149315226022823/0001493152-26-022823-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725430/000149315226022823/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T10:14:29.423393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}